Table 4.
Canonical Pathways Regulated in Proliferative Phase Endometrium From Women With Adenomyosis Versus Healthy Controls.
| Ingenuity Canonical Pathways | −Log (P Value) | P Value | Ratio | Molecules |
|---|---|---|---|---|
| EIF2 signaling | 1.06E01 | .00000 | 1.82E-01 | RAF1, RPL22, RPS18, RPS8, RPL14, EIF4A2, RPS21, RPS7, SHC1, RPL35, MAPK3, RPL36, RPL12, RPS24, RPL34, RPL27, RPS28, RPS19, RPL23A, RPLP0, RPS12, RPS29, FAU, RPS26, RPL26L1, RPS15A, RPS25, RPL39L, RPL38, RPLP1, RPL13A, RPL41, EIF3K |
| Oxidative phosphorylation | 7.55E00 | .00000 | 2.00E-01 | COX6B1, SDHB, ATP5O, UQCRH, COX6A1, UQCR11, ATP5G2, NDUFA1, ATP5E, COX7C, ATP5G1, NDUFAB1, NDUFA3, MT-ND2, UQCRQ, COX4I1, NDUFB2, ATP5I, NDUFA8, COX6C, NDUFS4 |
| Mitochondrial dysfunction | 5.86E00 | .00000 | 1.45E-01 | SDHB, COX6B1, ATP5O, UQCRH, COX6A1, UQCR11, XDH, NCSTN, ATP5G2, NDUFA1, ATP5E, COX7C, ATP5G1, NDUFAB1, CYB5R3, NDUFA3, MT-ND2, COX4I1, NDUFB2, UQCRQ, ATP5I, NDUFA8, COX6C, NDUFS4 |
| Estrogen receptor signaling | 5.36E00 | .00000 | 1.5E-01 | RAF1, CREBBP, RBFOX2, MED12, SMARCA4, MED27, G6PC3, MED14, TAF9B, PGR, EP300, SHC1, POLR2A, MED15, MAPK3, NCOR2, POLR2I, MED24, MED4, TAF15 |
| mTOR signaling | 4.37E00 | .00004 | 1.22E-01 | RPS28, RPS18, RPS19, FKBP1A, RPS8, EIF4A2, RPS21, PDGFC, RPS12, RPS7, RPS29, HMOX1, FAU, RPS26, MAPK3, RPS15A, PPP2R2C, RPS25, RHOF, PRKD1, EIF3K, EIF4B, RPS24 |
| Hepatic fibrosis/hepatic stellate cell activation | 4.22E00 | .00006 | 1.36E-01 | MYH10, IGFBP4, MYL6, TNFRSF1A, IGFBP5, MMP2, NFKB1, PDGFC, MET, CCL2, TIMP1, TGFB1, IGFBP3, IGF1R, MYH9, EDNRA, ECE1, A2M, TIMP2 |
| Inhibition of matrix metalloproteases | 4.09E00 | .00008 | 2.37E-01 | TIMP3, MMP7, ADAM12, TIMP1, MMP16, MMP14, MMP2, A2M, TIMP2 |
| Regulation of eIF4 and p70S6K signaling | 3.96E00 | .00011 | 1.2E-01 | RAF1, RPS28, RPS18, RPS19, RPS8, EIF4A2, RPS21, RPS12, RPS7, RPS29, SHC1, FAU, RPS26, MAPK3, RPS15A, PPP2R2C, RPS25, RPS24, EIF3K |
| Apoptosis signaling | 2.93E00 | .00117 | 1.3E-01 | ENDOG, ACIN1, TP53, RAF1, CAPN6, TNFRSF1A, MAPK3, CAPN1, PLCG1, NFKB1, MAP4K4, PARP1 |
| Huntington disease signaling | 2.84E00 | .00145 | 9.61E-02 | TP53, CAPN6, SDHB, REST, CREBBP, GNB2L1, HSPA5, VTI1B, SIN3A, EP300, TAF9B, GNG10, TGM2, SHC1, POLR2A, MAPK3, CAPN1, IGF1R, NCOR2, POLR2I, BET1L, PRKD1 |
| Aryl hydrocarbon receptor signaling | 2.46E00 | .00347 | 1.06E-01 | TP53, GSTM3, NFKB1, SMARCA4, EP300, TGM2, GSTM2, ALDH1A1, CYP1A2, MGST2, TGFB1, MAPK3, NCOR2, GSTP1, MCM7 |
| PPARα/RXRα activation | 2.42E00 | .00380 | 9.77E-02 | RAF1, ACOX1, CREBBP, CKAP5, PLCG1, NFKB1, MED12, TGS1, EP300, SHC1, TGFB1, MAPK3, PRKACA, NCOR2, PLCL1, MED24, MAP4K4 |
| Androgen signaling | 2.41E00 | .00389 | 9.92E-02 | CALR, GNB2L1, CREBBP, NFKB1, GNG10, EP300, GNAI2, SHC1, POLR2A, MAPK3, PRKACA, POLR2I, PRKD1 |
| Leukocyte extravasation signaling | 2.37E00 | .00427 | 9.69E-02 | TIMP3, MMP7, MYL6, MMP16, MMP14, JAM2, CXCL12, PLCG1, MMP2, GNAI2, TIMP1, CYBB, ARHGAP35, VCL, ACTN4, ARHGAP1, CTTN, PRKD1, TIMP2 |
| Bladder cancer signaling | 2.35E00 | .00447 | 1.24E-01 | TP53, RAF1, CDH1, MMP7, THBS1, MMP16, MMP14, MAPK3, MMP2, PDGFC, SIN3A |
Abbreviations: ATP, Adenosine triphosphate; EIF, eukaryotic initiation factor; HSPA, heat shock 70 kDa protein; mTOR, mammalian target of rapamycin; RP, ribosomal protein; COX, cytochrome c oxidase; UQCR, ubiquinol-cytochrome c reductase; NDUFAB1, NADH dehydrogenase (ubiquinone) 1, α/β subcomplex; MMP, matrix metalloproteinase; CALR, calreticulin; MYL, myosin light chain; GNB, guanine nucleotide binding protein. See Appendix 1.